Cargando…

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas

Temozolomide (TMZ) is considered a standard chemotherapeutic agent for glioblastoma (GBM). Characterizing the biological molecules and signaling pathways involved in TMZ sensitivity would be helpful for selecting therapeutic schemes and evaluating prognosis for GBM. Thus, in the present study, we se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Hong-Qing, Liu, Ang-Si, Zhang, Min-Jie, Liu, Hou-Jie, Meng, Xiao-Li, Qian, Hai-Peng, Wan, Jing-Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258082/ https://www.ncbi.nlm.nih.gov/pubmed/32528873 http://dx.doi.org/10.3389/fonc.2020.00669

Ejemplares similares

Identifying Differential Expression Genes and Prognostic Signature Based on Subventricular Zone Involved Glioblastoma
por: Yuan, Qing, et al.
Publicado: (2022)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma
por: Zhang, Guang-Tao, et al.
Publicado: (2023)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine
por: Rubino, Sebastian, et al.
Publicado: (2018)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy
por: Zheng, Lin, et al.
Publicado: (2021)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
por: Berberich, Anne, et al.
Publicado: (2020)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
por: Robins, H. Ian, et al.
Publicado: (2018)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide
por: Lo Dico, Alessia, et al.
Publicado: (2018)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma
por: Park, So Hee, et al.
Publicado: (2020)

Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma
por: Di Ianni, Natalia, et al.
Publicado: (2021)

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022)

Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas
por: Yin, An-An, et al.
Publicado: (2019)

Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide
por: Bobola, Michael S., et al.
Publicado: (2012)

Cost-Effectiveness of [(18)F] Fluoroethyl-L-Tyrosine for Temozolomide Therapy Assessment in Patients With Glioblastoma
por: Baguet, Tristan, et al.
Publicado: (2019)

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2020)

A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
por: Attarian, Fahimeh, et al.
Publicado: (2021)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Corrigendum: Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2021)

Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation In Vitro
por: Matteoni, Silvia, et al.
Publicado: (2021)

Cyclooxygenase-2 Upregulated by Temozolomide in Glioblastoma Cells Is Shuttled In Extracellular Vesicles Modifying Recipient Cell Phenotype
por: Lombardi, Francesca, et al.
Publicado: (2022)

HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma
por: Zhang, Zuo‐Xin, et al.
Publicado: (2023)

Imaging-Genomics in Glioblastoma: Combining Molecular and Imaging Signatures
por: Liu, Dongming, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Mutation Status and Rad51 Determine the Response of Glioblastoma to Multimodality Therapy with Cetuximab, Temozolomide, and Radiation
por: Wachsberger, Phyllis Rachelle, et al.
Publicado: (2013)

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers
por: Ntafoulis, Ioannis, et al.
Publicado: (2023)

A miR-137-XIAP axis contributes to the sensitivity of TRAIL-induced cell death in glioblastoma
por: Geng, Fenghao, et al.
Publicado: (2022)

Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA‐101 in glioblastoma
por: Cai, Tao, et al.
Publicado: (2018)

Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide
por: Feng, Jianbo, et al.
Publicado: (2020)

Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide
por: Potthoff, Anna-Laura, et al.
Publicado: (2019)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures
por: Alcaniz, Joshua, et al.
Publicado: (2023)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
por: Chai, Rui-Chao, et al.
Publicado: (2019)

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9hh1m1oama2tgukqnbmtjcmqd1